(Q50030031)

English

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.

scientific article published on 9 February 2018

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/29439857

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

1 reference

based on heuristic

inferred from title

Ulka Vaishampayan

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

Toni K Choueiri

14

object named as

Toni K Choueiri

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

author name string

Michael B Atkins

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

Elizabeth R Plimack

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

Igor Puzanov

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

Mayer N Fishman

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

David F McDermott

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

Daniel C Cho

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

Saby George

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

Thomas E Olencki

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

Jamal C Tarazi

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

Brad Rosbrook

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

Kathrine C Fernandez

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

Mariajose Lechuga

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

publication date

9 February 2018

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/29439857

Lancet Oncology Commission

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

19

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

405-415

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular mechanisms of resistance to tumour anti-angiogenic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitory B7-family molecules in the tumour microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A modified toxicity probability interval method for dose-finding trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting the tumor vasculature to enhance T cell activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Control of the immune response by pro-angiogenic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930081-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(18)30081-0

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6860026&resulttype=core&format=json

13 May 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50030031&oldid=1516759251"